Omeprazole
delayed-release capsules in combination with other medications are
used to eliminate H. pylori, a bacteria causing ulcers and prevent
the development of new ulcers in people with a history of ulcer
formation of the small intestine. Prescription omeprazole is also
used to treat higher acid producing stomach conditions such as
Zollinger-Ellison syndrome in adults. According to the survey by
Clinical Gastroenterology and Hepatology, 2012, ZES occurs in about
one in every 1 million people, and is more common among men 30 to 50
years old.
Market Dynamics
Increasing prevalence of acid related diseases (ARDs) including
gastroesophageal reflux disease (GERD) is a major factor driving
omeprazole market growth. According to the research survey conducted
by Florida Hospitals, 2015, pregnant women are at a higher risk of
acid reflux, with an estimated 25% pregnant women experiencing the
symptoms. The survey further stated that about 20% of people with
acid reflux are at a higher risk of developing gastroesophageal
reflux disease (GERD). Furthermore, increase in H.pylori infection
and NSAID associated gastric and duodenal ulcers are expected to
bolster market growth in the near future.
For
In-Depth Review | Get Sample Copy @
https://www.coherentmarketinsights.com/insight/request-sample/2380
Also, launch of low-cost generic versions of omeprazole is expected
to fuel market growth. For instance, in 2016, Dr. Reddy’s launched
generic version to Zegerid capsules (omeprazole/sodium bicarbonate)
for short-term treatment of stomach and duodenal ulcers, erosive
esophagitis and heartburn associated with gastroesophageal reflux
disease (GERD).
Increasing prevalence of peptic ulcers is expected to propel
omeprazole market growth
Increasing prevalence of duodenal ulcers is expected to propel growth
of the omeprazole market. According to a survey by Virtual Medical
Center, 2016, peptic ulcer is the most common disease occurring in
about 10-15% of the global population at a time. It is common in men
and more common in elderly people. The survey further stated that
duodenal ulcers are four times more common than gastric ulcers.
Increasing prevalence of H.pylori associated infection and
favorable pricing policies to bolster the market growth
North America is expected to hold a dominant position in the global
omeprazole market. This is owing to increasing number of people
affected by H.pylori infection, which in turn is expected to increase
the risk of gastric and duodenal ulcers. According to the National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),
Health Information Center, 2014, about 30 to 40 percent of people in
the U.S. suffer from the H. pylori infection, thus increasing the
risk of duodenal and gastric development.
Key Players
Major players operating in the global omeprazole market include,
Astrazeneca Plc., Sandoz, Inc., Mylan N.V., Apotex, Inc., Dr. Reddy’s
Laboratories, Inc., Impax Laboratories, Inc., Perrigo Company Plc,
Santarus, Inc., Watson laboratories, Inc., and Lek Pharmaceuticals
d.d.
Detailed Segmentation:
Global Omeprazole Market, By Dosage Form:
-
Capsule
-
Powder
-
Tablet
Global Omeprazole Market, By Indication:
-
Duodenal Ulcer
-
Gastric Ulcer
-
Gastroesophageal Reflux Disease (GERD)
-
Erosive Esophagitis
-
Others
Browse
Complete Research Report @
https://www.coherentmarketinsights.com/market-insight/omeprazole-market-2380
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
No comments:
Post a Comment